A zithromycin is one of the most widely used antibiotics in clinical practice. More than 50 million prescriptions are issued in the United States annually, typically for respiratory tract and sexually transmitted infections. The drug has become popular be cause of its broad spectrum of antimicrobial activity, convenience of dosing and favourable drug interaction profile relative to its predeces sors erythromycin and clarithromycin. 1 It has also been considered relatively safe; however, in 2012, a widely publicized study raised con cerns about its cardiovascular safety. Subse quent studies suggested these concerns may have been overstated.
In 2012, the New England Journal of Medicine (NEJM) published a study involving the health records of Medicaid recipients in Tennes see. 2 The study found that azithromycin was associated with an increased risk of cardiovascu lar death relative to amoxicillin (odds ratio 2.49, 95% confidence interval [CI] 1.38-4.50). 2 The publication spawned extensive media coverage, with headlines that grew even more disquieting following a review of the available data by the US Food and Drug Administration (FDA).
A year later, NEJM published a study from Denmark involving 1.1 million treatment courses of azithromycin, which found no in creased risk of cardiovascular death relative to penicillin V (rate ratio 0.93, 95% CI 0.56-1.55). 3 This study garnered considerably fewer head lines, but was accompanied by a commentary from officials at the FDA, 4 which had only a few months earlier strengthened its warnings about the cardiac risk of azithromycin. 5 The authors argued that the new study did not exclude an increased cardiovascular risk because it involved patients who were relatively healthy. 4 The 2012 study was predicated on the observa tion that azithromycin can prolong the QT inter val. 2 A prolonged QT interval is a major risk fac tor for torsades de pointes, the same potentially lethal arrhythmia responsible for the disappear ance from pharmacy shelves of terfenadine, cis apride, astemizole and grepafloxacin. Although azithromycin can cause QT prolongation, 6 it does so to a lesser extent than either erythromycin or clarithromycin. 7, 8 Moreover, despite the wide spread use of azithromycin, reports of torsades de pointes in patients taking this drug are exceed ingly rare, and almost all of them involve patients with other risk factors for QT prolongation. 6 Con sequently, the role of azithromycin in each case is unclear. In a metaanalysis of six randomized tri als comparing azithromycin with placebo in almost 14 000 patients with established coronary disease -an inherently highrisk groupazithromycin was associated with a trend toward reduced mortality (odds ratio 0.91, 95% CI 0.77-1.09). 9 Finally, a recent observational study involving more than 70 000 adults admitted to hospital with pneumonia found that treatment with azithromycin was associated with lower 90day mortality and no increase in arrhythmias. 10 From these observations, it is tempting to specu late that azithromycin may not be as dangerous as the initial headlines suggested.
The two studies published in NEJM most likely reached different conclusions because they involved patients with different characteristics. 2, 3 In the first study, azithromycin recipients were on average nine years older (49 v. 40 yr) and much more likely to have received βadrenergic block ers (21.5% v. 4 • Recent studies have yielded conflicting information about the cardiovascular safety of azithromycin.
• The association between azithromycin and cardiovascular death most likely represents the effects of infection rather than a direct effect of the drug.
• Although azithromycin can influence cardiac conduction, adverse consequences are largely confined to patients with established cardiac disease.
• Caution is warranted when prescribing azithromycin to patients with pre-existing QT prolongation or risk factors for it, including hypokalemia, hypomagnesemia and use of other QT-prolonging drugs.
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The clinically important question, however, is whether azithromycin itself causes cardiovascu lar death or is simply a marker of increased risk. Patients who are sick enough to warrant broad spectrum antibiotics sometimes die, particularly when burdened with comorbidities. To enhance inferences regarding causality of the association between azithromycin and risk of cardiovascular death, the 2012 study employed a variety of approaches, including a comparison with amoxi cillin. 2 The problem here is obvious: amoxicillin and azithromycin are prescribed for very differ ent indications. This was borne out in the study; 45% of azithromycin recipients with a docu mented indication for treatment had an infection of the lower respiratory tract, compared with only 27% of amoxicillin recipients. Moreover, azithromycin was not associated with an increased risk of cardiovascular death relative to levofloxacin, a more clinically appropriate com parator, albeit one that itself can sometimes cause QT prolongation.
The authors also explored azithromycin's safety as a function of baseline cardiovascular risk and found the strongest "signal" in patients with the highest baseline risk. This too is not sur prising, because the patients least able to tolerate a serious infection (of the lower respiratory tract in particular) are those with severe cardiovascu lar disease. It is therefore likely that many, if not most, cases of sudden death during azithromycin therapy were the result of infections in medically frail patients, rather than the direct effect of the drug itself.
Relative risk estimates can be misleading, particularly when applied to rare but serious events. Because clinicians generally prefer to think in numbers rather than rates, what matters most when making clinical decisions is the abso lute risk (or benefit) of an intervention, rather than relative estimates. In both studies, 2,3 fewer than 100 deaths occurred per million prescrip tions for azithromycin. For contextual purposes, let us assume that half of all sudden deaths in the 2012 study were directly caused by azithromycin -an implausibly high proportion. A physician caring for similar patients would need to issue 20 azithromycin prescriptions every working day for about six years to trigger one arrhythmic death.
Physicians should not be reluctant to prescribe azithromycin when a valid indication is present.
For most patients, the absolute risk of a serious arrhythmia is infinitesimal. However, because the drug does carry risk, it remains prudent to pre scribe azithromycin cautiously, particularly in patients susceptible to arrhythmia, such as those with baseline QT prolongation, hypokalemia or hypomagnesemia, as well as those taking sotalol, methadone or other drugs with similar effects on repolarization.
11 Even in these patients, however, treatment with a macrolide will occasionally be unavoidable. In such instances, the safest course of action is to correct reversible causes of QT prolongation while limiting the dose and duration of antibiotic therapy. In patients who have an especially high risk of arrhythmia, periodic moni toring with electrocardiography during therapy offers an additional measure of safety.
